Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis: A Multicenter, Real-world and Respective Study

NCT04160897 is registered in ClinicalTrials.gov with Qing XIe as lead sponsor.

NCT NCT04160897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04160897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis: A Multicenter, Real-world and Respective Study
Lead sponsor
Qing XIe
Phase
Observational
Overall status
Unknown status
Start date
October 22, 2019
Completion date
October 31, 2020
Enrollment
4,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

compensated cirrhosis, hepatitis b, chronic, hepatocellular carcinoma